Trending at Lumira Ventures

Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

jacki jenuth Celtaxsys, Portfolio News

Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients  Celtaxsys, with continued support from the CF Foundation, has commenced preparations for designing and executing …

Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines

jacki jenuth Celtaxsys, Portfolio News

New patents build on previously granted composition of matter protection for acebilustat, with additional intellectual protection for use in cystic fibrosis, as well as new compositions for second generation anti-inflammatory molecules Acebilustat, the most advanced new candidate in the CF …

Celtaxsys Announces Publication of Results Demonstrating the Safety, Tolerability and Optimal PK/PD Profile of First-In-Class Anti-Inflammatory Medicine, Oral Acebilustat, in Phase 1 Clinical Trials Including Cystic Fibrosis Patients

admin Celtaxsys, Portfolio News

ATLANTA, GA–(Marketwired – October 28, 2016) – Celtaxsys, Inc., a clinical stage drug development company focused on advancing therapies for patients with rare inflammatory diseases, announced today the publication of the first in a series of papers detailing the results …

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

admin Celtaxsys, Portfolio News

ATLANTA, June 2, 2015 /PRNewswire/ — Celtaxsys, a clinicalstage drug development company focused on advancing care for patients sufferingfrom inflammatory diseases, including those with rare and orphan inflammatorydiseases, announced today that it has received a development award for $5million from …